Education
About Us
Working with TipRanks
Follow Us
Adaptimmune Therapeutics (ADAP)
NASDAQ:ADAP
Earnings Data
Report Date
Nov 05, 2025Before Open (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.05Last Year’s EPS
-0.01Same Quarter Last Year
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Adaptimmune reported a very successful launch of TECELRA with strong initial sales and effective patient access. The early activation of treatment centers and manufacturing success further support their positive outlook. However, financial challenges remain with doubts about their ability to continue as a going concern.Company Guidance
Strong TECELRA Launch with Revenue Guidance
Adaptimmune reported a successful launch of TECELRA with 21 patients apheresed in 2025, 13 in Q1 and 8 in early Q2. They provided revenue guidance for the full year of $35 million to $45 million in TECELRA sales.
Early Activation of Treatment Centers
Adaptimmune has 28 treatment centers accepting referrals and expects to have a full network of 30 centers by the end of 2025, a year earlier than expected.
100% Manufacturing Success
The TECELRA manufacturing center in Philadelphia reported 100% success with all doses released meeting specifications, and an average turnaround time of 27 days, beating the target of 30 days.
No Patient Denials
Effective patient access to TECELRA with no patient denials reported to date.
Future Growth with lete-cel
Anticipation of lete-cel approval in 2026, which could more than double the addressable patient market within the sarcoma franchise.
ADAP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ADAP Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 13, 2025 | $0.08 | $0.08 | 0.00% |
May 13, 2025 | $0.30 | $0.25 | -16.67% |
Mar 20, 2025 | $0.45 | $0.28 | -37.78% |
Nov 13, 2024 | $0.77 | $0.59 | -23.38% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Adaptimmune Therapeutics (ADAP) report earnings?
Adaptimmune Therapeutics (ADAP) is schdueled to report earning on Nov 05, 2025, Before Open (Confirmed).
What is Adaptimmune Therapeutics (ADAP) earnings time?
Adaptimmune Therapeutics (ADAP) earnings time is at Nov 05, 2025, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ADAP EPS forecast?
ADAP EPS forecast for the fiscal quarter 2025 (Q3) is -0.05.
